RXRX
Recursion Pharmaceuticals Inc.
$2.95
-$0.06(-2.16%)
45
Overall
60
Value
33
Tech
44
Quality
Market Cap
$2.54B
Volume
22.41M
52W Range
$2.77 - $7.18
Target Price
$6.64
Order:
Income Statement
| Metric | Trend | Chart | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Total Revenue | $10.2M | $39.8M | $44.6M | $58.8M | $74.7M | ||
| Total Revenue | $10.2M | $39.7M | $44.6M | $58.8M | $74.7M | ||
| COST OF GOODS SOLD | |||||||
| Cost of Revenue | -- | $48.3M | $42.6M | $45.2M | $71.0M | ||
| GROSS PROFIT | |||||||
| Gross Profit | $10.2M | $-8.6M | $2.0M | $13.6M | $3.7M | ||
| OPERATING EXPENSES | |||||||
| Operating Expenses | $193.0M | $237.1M | $352.0M | $492.6M | $651.9M | ||
| Research & Development | $135.3M | $155.7M | $241.2M | $314.4M | $475.3M | ||
| Research Expense | $135.3M | $155.7M | $241.2M | $314.4M | $475.3M | ||
| Selling, General & Administrative | $57.7M | $81.6M | $110.8M | $178.2M | $176.6M | ||
| General & Administrative Expenses | $57.7M | $81.6M | $110.8M | $178.2M | $176.6M | ||
| Salaries & Wages | -- | $26.9M | -- | -- | -- | ||
| Depreciation & Amortization | $8.8M | $11.4M | $24.4M | $36.5M | -- | ||
| Depreciation & Amortization | $8.8M | $11.4M | -- | -- | -- | ||
| Amortization | $1.4M | $1.3M | $52.1M | $339.9M | -- | ||
| Other Operating Expenses | -- | $-818.0K | -- | -- | -- | ||
| OPERATING INCOME | |||||||
| Operating income | $-182.8M | $-245.7M | $-350.1M | $-479.0M | $-648.1M | ||
| EBITDA | $-175.1M | $-288.9M | $-307.7M | $-428.3M | $-561.2M | ||
| NON-OPERATING ITEMS | |||||||
| Interest Expense (Non-Operating) | $3.0M | $55.0K | -- | $1.6M | -- | ||
| Intinc | -- | -- | -- | $15.8M | -- | ||
| Net Non-Operating Interest Income/Expense | $-2.9M | $6.2M | -- | -- | -- | ||
| Gain on Sale of Securities | $73.0K | $6.3M | -- | -- | -- | ||
| Other Income/Expense | $3.7M | $52.0K | $-17.9M | $-14.2M | $-3.2M | ||
| Other Special Charges | $-3.7M | $6.3M | $17.9M | $14.2M | $3.2M | ||
| PRE-TAX INCOME | |||||||
| EBIT | $-183.5M | $-300.6M | $-332.1M | $-464.8M | $-644.9M | ||
| Pre-Tax Income | $-186.5M | $-239.5M | $-332.1M | $-464.8M | $-644.9M | ||
| INCOME TAX | |||||||
| Tax Provision | $-46.6M | $-61.2M | $-4.1M | $-1.1M | $-136.0K | ||
| NET INCOME | |||||||
| Net Income | $-186.5M | $-239.5M | $-328.1M | $-463.7M | $-644.8M | ||
| Net Income (Continuing Operations) | $-186.5M | $-239.5M | $-328.1M | $-463.7M | $-644.8M | ||
| Net Income (Discontinued Operations) | $-186.5M | $-239.5M | $-328.1M | $-463.7M | $-644.8M | ||
| Net Income (Common Stockholders) | $-186.5M | $-239.5M | $-328.1M | $-463.7M | $-644.8M | ||
| Normalized Income | -- | -- | -- | -- | $-645.0M | ||
| TOTALS | |||||||
| Total Expenses | $193.0M | $285.4M | $394.6M | $537.8M | $722.8M | ||
| SHARE & EPS DATA | |||||||
| Average Shares Outstanding | $125.3M | $175.5M | $207.9M | $274.2M | $447.4M | ||
| Average Shares Outstanding (Diluted) | $125.3M | $175.5M | $207.9M | $274.2M | $447.4M | ||
| Shares Outstanding | $170.8M | $191.2M | $234.7M | $402.0M | $527.4M | ||
| Basic EPS | $-1.49 | $-1.36 | $-1.58 | $-1.69 | $-1.44 | ||
| Basic EPS (Continuing Operations) | $-1.49 | $-1.36 | $-1.58 | $-1.69 | $-1.44 | ||
| Diluted EPS | $-1.49 | $-1.36 | $-1.58 | $-1.69 | $-1.44 | ||
| Diluted EPS (Continuing Operations) | $-1.49 | $-1.36 | $-1.58 | $-1.69 | $-1.44 | ||
| OTHER METRICS | |||||||
| Other Gand A | $57.7M | $81.6M | $110.8M | $178.2M | $176.6M | ||
| Rent And Landing Fees | $6.4M | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RXRX | $2.95 | -2.2% | 22.41M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Recursion Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW